Travere Therapeutics, Inc., (TVTX) is approaching a key regulatory milestone as the U.S. FDA evaluates the company's supplemental New Drug Application for FILSPARI in focal segmental glomerulosclerosis. The agency in January 2026 extended its review, assigning a new PDUFA target action date of April 13, 2026.
If approved FILSPARI would become the first FDA-approved therapy for FSGS, a rare, progressive kidney disorder characterized by progressive scarring of the kidney, persistent proteinuria, and a high risk of progression to end-stage kidney disease. The condition affects an estimated 40,000 patients in the United States, with a similar prevalence in Europe.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.